Market accessCompany release

China adds Ascentage's lisaftoclax to NRDL; olverembatinib coverage renewed after renegotiation

Ascentage Pharma Group International (AAPG) · Mon 16 Nov 2026

Ascentage Pharma says its Bcl-2 inhibitor lisaftoclax enters China's reimbursement list for the first time, while olverembatinib keeps its place after renegotiation.

Ascentage Pharma announced on 16 November 2026 that lisaftoclax, its Bcl-2 inhibitor, has been included in China's National Reimbursement Drug List (NRDL) for the first time. The listing covers adults with relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have already received therapy that included a BTK inhibitor.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Ascentage Pharma Group International ↗

Article written by VigiEye from the official source (Ascentage Pharma Group International). Claims are the company's own. AI-assisted; check the source before acting.